1. Market Research
  2. > Pain – Pipeline Review, H1 2013

Pain – Pipeline Review, H1 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 404 pages

Pain – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Pain - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pain. Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pain.
- A review of the Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pain pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pain pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Pain - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
Introduction 10
Pain Overview 11
Therapeutics Development 12
Pain Therapeutics under Development by Companies 14
Pain Therapeutics under Investigation by Universities/Institutes 32
Late Stage Products 35
Mid Clinical Stage Products 36
Early Clinical Stage Products 37
Discovery and Pre-Clinical Stage Products 38
Pain Therapeutics - Products under Development by Companies 39
Pain Therapeutics - Products under Investigation by Universities/Institutes 71
Companies Involved in Pain Therapeutics Development 73
Pain - Therapeutics Assessment 265
Drug Profiles 273
Pain Therapeutics - Drug Profile Updates 332
Pain Therapeutics - Discontinued Products 354
Pain Therapeutics - Dormant Products 362
Pain - Product Development Milestones 388
Appendix 394



List of Tables

Number of Products Under Development for Pain, H1 2013 21
Products under Development for Pain - Comparative Analysis, H1 2013 22
Number of Products under Development by Companies, H1 2013 24
Number of Products under Investigation by Universities/Institutes, H1 2013 42
Comparative Analysis by Late Stage Development, H1 2013 44
Comparative Analysis by Mid Clinical Stage Development, H1 2013 45
Comparative Analysis by Early Clinical Stage Development, H1 2013 46
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 47
Products under Development by Companies, H1 2013 48
Products under Investigation by Universities/Institutes, H1 2013 80
Bristol-Myers Squibb Company, H1 2013 82
DURECT Corporation, H1 2013 83
Boehringer Ingelheim GmbH, H1 2013 84
Biogen Idec Inc., H1 2013 85
Allergan, Inc., H1 2013 86
Shionogi and Co., Ltd., H1 2013 87
AlphaRx, Inc., H1 2013 88
Amgen Inc., H1 2013 89
Sanofi-Aventis, H1 2013 90
AstraZeneca PLC, H1 2013 91
Questcor Pharmaceuticals, Inc., H1 2013 92
BioDelivery Sciences International, Inc., H1 2013 93
GlaxoSmithKline plc, H1 2013 94
Nektar Therapeutics, H1 2013 95
MedImmune LLC, H1 2013 96
Alkermes, Inc., H1 2013 97
Daiichi Sankyo Company, Ltd, H1 2013 98
Merck and Co., Inc., H1 2013 99
Sangamo BioSciences, Inc., H1 2013 100
Infinity Pharmaceuticals, Inc., H1 2013 101
Generex Biotechnology Corporation, H1 2013 102
Takeda Pharmaceutical Company Limited, H1 2013 103
Egalet a/s, H1 2013 104
Meytav Technological Incubator, H1 2013 105
Ipsen S.A., H1 2013 106
Acusphere, Inc., H1 2013 107
Zogenix, Inc., H1 2013 108
Neurocrine Biosciences, Inc., H1 2013 109
Biofrontera AG, H1 2013 110
Pacira Pharmaceuticals, Inc., H1 2013 111
Novartis AG, H1 2013 112
Aphios Corporation, H1 2013 113
AcelRx Pharmaceuticals, Inc., H1 2013 114
Astellas Pharma Inc., H1 2013 115
Axcan Pharma Inc., H1 2013 116
Cubist Pharmaceuticals, Inc., H1 2013 117
Daewoong Pharmaceutical Co., Ltd., H1 2013 118
Dr. Reddy's Laboratories Limited, H1 2013 119
Esteve Group, H1 2013 120
Glenmark Pharmaceuticals Ltd., H1 2013 121
Kowa Company, Ltd., H1 2013 122
Laboratoires Pierre Fabre SA, H1 2013 123
Nippon Kayaku Co., Ltd., H1 2013 124
Nippon Shinyaku Co., Ltd., H1 2013 125
Orion Corporation, H1 2013 126
Pain Therapeutics, Inc., H1 2013 127
Pfizer Inc., H1 2013 128
Purdue Pharma L.P., H1 2013 129
Teva Pharmaceutical Industries Limited, H1 2013 130
Zambon Group S.p.A., H1 2013 131
Sun Pharmaceutical Industries Limited, H1 2013 132
TransPharma Medical Ltd., H1 2013 133
Menarini Group, H1 2013 134
Bayer AG, H1 2013 135
IBSA Institut Biochimique SA, H1 2013 136
Zosano Pharma, Inc., H1 2013 137
TheraKine Inc., H1 2013 138
Collegium Pharmaceutical, Inc., H1 2013 139
Capnia, Inc., H1 2013 140
Acura Pharmaceuticals, Inc., H1 2013 141
Alchemia Limited, H1 2013 142
Addex Pharmaceuticals, H1 2013 143
Evotec Aktiengesellschaft, H1 2013 144
GW Pharmaceuticals plc, H1 2013 145
Anavex Life Sciences Corp., H1 2013 146
IntelGenx Technologies Corp., H1 2013 147
Can-Fite BioPharma Ltd., H1 2013 148
Lupin Limited, H1 2013 149
Benitec Ltd., H1 2013 150
Bionomics Limited, H1 2013 151
NeuroDiscovery Ltd, H1 2013 152
NeurogesX, Inc., H1 2013 153
NeuroSearch A/S, H1 2013 154
NexMed, Inc., H1 2013 155
NovaDel Pharma, Inc., H1 2013 156
Columbia Laboratories Inc., H1 2013 157
Nutra Pharma Corporation, H1 2013 158
Nuvo Research Inc., H1 2013 159
Paladin Labs Inc., H1 2013 160
ACADIA Pharmaceuticals Inc., H1 2013 161
MAP Pharmaceuticals, Inc., H1 2013 162
Arena Pharmaceuticals, Inc., H1 2013 163
CombinatoRx, Incorporated, H1 2013 164
Hisamitsu Pharmaceutical Co., Inc., H1 2013 165
Titan Pharmaceuticals, Inc., H1 2013 166
Urigen Pharmaceuticals, Inc., H1 2013 167
POZEN Inc., H1 2013 168
Array BioPharma Inc., H1 2013 169
Choongwae Pharma Corp, H1 2013 170
Ahn-Gook Pharmaceutical Co., Ltd., H1 2013 171
PhytoHealth Corporation, H1 2013 172
Diamyd Medical AB, H1 2013 173
Neurim Pharmaceuticals (1991) Ltd., H1 2013 174
Pluristem Therapeutics Inc., H1 2013 175
Theravance, Inc., H1 2013 176
Suven Life Sciences Ltd., H1 2013 177
ProStrakan Group plc, H1 2013 178
Orexo AB, H1 2013 179
Plethora Solutions Holdings plc, H1 2013 181
Proximagen Neuroscience plc., H1 2013 182
Newron Pharmaceuticals S.p.A., H1 2013 183
Teikoku Pharma USA, Inc., H1 2013 184
Labtec GmbH, H1 2013 185
Xel Pharmaceuticals, Inc., H1 2013 186
Intas Pharmaceuticals Ltd., H1 2013 187
Angelini Group, H1 2013 188
Debiopharm Group, H1 2013 189
D-Pharm Ltd., H1 2013 190
Axxam SpA, H1 2013 191
Chromocell Corporation, H1 2013 192
BCN Peptides S.A., H1 2013 193
Lehigh Valley Technologies, Inc., H1 2013 194
Camurus AB, H1 2013 195
Immupharma Plc, H1 2013 196
Palau Pharma S.A, H1 2013 197
Probiodrug AG, H1 2013 198
Phosphagenics Limited, H1 2013 199
Abiogen Pharma S.p.A., H1 2013 200
Physica Pharma, H1 2013 201
Neorphys, H1 2013 202
Transdel Pharmaceuticals, Inc., H1 2013 203
Grunenthal GmbH, H1 2013 204
Xenon Pharmaceuticals Inc., H1 2013 205
Oncodesign SA, H1 2013 206
Ache Laboratorios Farmaceuticos S/A, H1 2013 207
Ascent Therapeutics, H1 2013 208
Alder Biopharmaceuticals Inc., H1 2013 209
AngioChem Inc., H1 2013 210
Global Health Ventures Inc., H1 2013 211
PharmEste, H1 2013 212
CoLucid Pharmaceuticals, Inc., H1 2013 213
Charleston Laboratories, Inc., H1 2013 214
Trevena, Inc., H1 2013 215
PLx Pharma Inc., H1 2013 216
Pantarhei Bioscience BV, H1 2013 217
Solace Pharmaceuticals, H1 2013 218
Kineta, Inc., H1 2013 219
WEX Pharmaceuticals Inc., H1 2013 220
Hydra Biosciences, Inc., H1 2013 221
NeurAxon, Inc., H1 2013 222
Selexys Pharmaceuticals Corporation, H1 2013 223
SeneXta Therapeutics SA, H1 2013 224
Monosol Rx, LLC, H1 2013 225
QRxPharma Limited, H1 2013 226
Omeros Corporation, H1 2013 227
Shin Nippon Biomedical Laboratories, Ltd., H1 2013 228
Cara Therapeutics, Inc., H1 2013 229
AIKO Biotechnology, Inc., H1 2013 230
Amneal Pharmaceuticals, L.L.C., H1 2013 231
APEIRON Biologics AG, H1 2013 232
PepTcell Limited, H1 2013 233
Tragara Pharmaceuticals, Inc., H1 2013 234
Tris Pharma, Inc., H1 2013 235
Intellipharmaceutics International Inc., H1 2013 236
Xenome Ltd., H1 2013 237
Iroko Pharmaceuticals, LLC, H1 2013 238
K.U.Leuven Research and Development, H1 2013 239
KYORIN Pharmaceutical Co., Ltd., H1 2013 240
Winston Pharmaceuticals, Inc., H1 2013 241
Maruho Co.,Ltd., H1 2013 242
FemmePharma Global Healthcare, Inc., H1 2013 243
Medestea Research and Production S.p.A., H1 2013 244
Encore Therapeutics Inc., H1 2013 245
NeuroTherapeutics Pharma Inc., H1 2013 246
Proreo Pharma AG, H1 2013 247
Bial - Portela and Ca, S.A., H1 2013 248
CLL Pharma, H1 2013 249
THERABEL Pharma NV, H1 2013 250
TOKUHON Corporation, H1 2013 251
KemPharm, Inc., H1 2013 252
Spinifex Pharmaceuticals Pty Limited, H1 2013 253
Sinil Pharma Ltd., H1 2013 254
Heptares Therapeutics Ltd., H1 2013 255
Envoy Therapeutics, Inc., H1 2013 256
Flexion Therapeutics, H1 2013 257
BioProspecting NB, Inc., H1 2013 258
MAKScientific, LLC, H1 2013 259
Troikaa Pharmaceuticals Ltd., H1 2013 260
BHR Pharma, LLC., H1 2013 261
SelectX Pharmaceuticals, Inc., H1 2013 262
TheraQuest Biosciences, LLC, H1 2013 263
Afferent Pharmaceuticals, Inc., H1 2013 264
iCeutica, Inc., H1 2013 265
Trigemina, Inc., H1 2013 266
NAL Pharmaceuticals Ltd., H1 2013 267
Reviva Pharmaceuticals Inc., H1 2013 268
RaQualia Pharma Inc., H1 2013 269
Atlantic Healthcare Limited, H1 2013 270
Mt Cook Pharma. Inc., H1 2013 271
Cytogel Pharma, LLC, H1 2013 272
Madeira Therapeutics, H1 2013 273
Assessment by Monotherapy Products, H1 2013 274
Assessment by Combination Products, H1 2013 275
Assessment by Stage and Route of Administration, H1 2013 278
Assessment by Stage and Molecule Type, H1 2013 281
Pain Therapeutics - Drug Profile Updates 341
Pain Therapeutics - Discontinued Products 363
Pain Therapeutics - Dormant Products 371



List of Figures

Number of Products under Development for Pain, H1 2013 21
Products under Development for Pain - Comparative Analysis, H1 2013 22
Products under Development by Companies, H1 2013 23
Products under Investigation by Universities/Institutes, H1 2013 41
Late Stage Products, H1 2013 44
Mid Clinical Stage Products, H1 2013 45
Early Clinical Stage Products, H1 2013 46
Discovery and Pre-Clinical Stage Products, H1 2013 47
Assessment by Monotherapy Products, H1 2013 274
Assessment by Combination Products, H1 2013 275
Assessment by Route of Administration, H1 2013 276
Assessment by Stage and Route of Administration, H1 2013 277
Assessment by Molecule Type, H1 2013 279
Assessment by Stage and Molecule Type, H1 2013 280

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.